As the U.S. health care market evolves toward a system that better recognizes and rewards value, we need to focus on pragmatic solutions that address regulations that increase uncertainty and unpredictability for payers and manufacturers and make it more difficult to explore innovative payment arrangements.
Current rules prohibit discussions between insurance companies and biopharmaceutical companies about medicines that are on the horizon. This doesn’t give insurers the opportunity to plan their budgets, causing uncertainty about insurance premiums and other planning tools. Similarly, once a medicine is available for patients, current rules prevent manufacturers from sharing research—including FDA-requested research—with insurers and doctors, including the results of trials, data on specific patient populations use of the medicine and more. In order for biopharmaceutical companies to become partners—rather than simply vendors—we need to be able to communicate with payers about the performance of our products. Removing these barriers will promote efficiency and affordability and ensure the right drug is getting to the right patient at the right time.